$PTIX Cashflow Statement | Understand Stock

$PTIX

$0.74 +$0.00 (0.0%) Close

$PTIX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2026 12 months to Mar 31, 2026	FY2025 12 months to Dec 31, 2024	FY2024 12 months to Dec 31, 2023	FY2023 12 months to Dec 31, 2022	FY2022 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss)
Adjustments to reconcile net income/loss to net cash flows used in operating activities:
Amortization of debt discount to interest expense
Gain on settlement of accounts payable and accrued liabilities with related parties
Stock based compensation
Derivative expense
Change in fair value of derivative liabilities
Depreciation expense
Stock-based compensation
Realized loss on sale of marketable securities
Realized (gain) loss on sale of marketable securities
Gain/loss on disposal of subsidiary
Gain/loss on extinguishment of debt
Inventories
Prepaid expenses
Accounts payable and accrued expenses
Accounts payable and accrued expenses – related party
VAT receivable
Accounts payable
Accrued liabilities
Net cash used in operating activities
Proceeds from sale of marketable securities
Proceeds from sale of marketable securities
Purchase of marketable securities
Cash received in acquisition of Phytanix Bio
Cash spent on unwind of Phytanix Bio acquisition
Purchase of fixed assets
Net cash provided by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Exercise of warrants for cash
Exercise of options for cash
Proceeds from notes payable
Repayment of notes payable
Issuance of shares and warrants from offering, net of offering costs

Increase in note payable for acquisition of Phytanix Bio
Proceeds from exercise of warrants
Proceeds from related party loans
Net cash provided by financing activities
NET INCREASE IN CASH
Effect of exchange rate adjustments on cash
NET CHANGE IN CASH
CASH, BEGINNING OF THE PERIOD
CASH, END OF THE PERIOD
CASH, beginning of period
CASH, end of period
NON-CASH INVESTING AND FINANCING INFORMATION:
Shares issued for conversion of notes and interest
Unrealized loss on marketable securities
Unrealized gain or loss on marketable securities
Net assets acquired of Phytanix Bio, net of cash paid
Shares issued for warrant exercises

Comments